Abstract
No public abstract is available from the verified source records.
Keyun Fu, Qi Qin, Maohua Li, Shasha Xiao, Lunchang Wang, Jiehua Li
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Current treatment of in-stent restenosis
10.1016/j.jacc.2014.02.545 · 2014
Coronary in-stent restenosis: JACC state-of-the-art review
10.1016/j.jacc.2022.05.017 · 2022
From mechanisms to management: tackling in-stent restenosis in the drug-eluting stent era
10.1007/s11886-025-02193-z · 2025
Neointimal hyperplasia
2019
Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways
10.1016/j.biotechadv.2018.04.006 · 2018
Molecular factors involved in the mechanism of intimal hyperplasia: a systematic review
10.1177/00033197251413811 · 2026
Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis
10.1016/j.jcin.2011.05.025 · 2011
Transcriptional and epigenetic regulation of macrophages in atherosclerosis
10.1038/s41569-019-0265-3 · 2020
Artesunate inhibits neointimal hyperplasia by promoting IRF4 associated macrophage polarization
2025
The P2X7 receptor in infection and inflammation
Confidence 0%
10.1016/j.immuni.2017.06.020 · 2017
P2X7 receptors: an untapped target for the management of cardiovascular disease
10.1161/atvbaha.120.315116 · 2021
P2X7 receptor antagonism modulates IL-1β and MMP9 in human atherosclerotic vessels
10.1038/s41598-017-05137-y · 2017
Cathelicidin aggravates myocardial ischemia/reperfusion injury via activating TLR4 signaling and P2X(7)R/NLRP3 inflammasome
10.1016/j.yjmcc.2019.12.011 · 2020
P2X7 receptor is essential for ST36-attenuated cardiac fibrosis upon beta-adrenergic insult
10.1007/s11302-024-10009-y · 2025
The role of the ATP-adenosine axis in ischemic stroke
10.1007/s00281-023-00987-3 · 2023
Purinergic receptor P2X7 contributes to abdominal aortic aneurysm development via modulating macrophage pyroptosis and inflammation
10.1016/j.trsl.2023.03.002 · 2023
P2X(7) deficiency blocks lesional inflammasome activity and ameliorates atherosclerosis in mice
10.1161/circulationaha.117.027400 · 2017
HMGB1-driven inflammation and intimal hyperplasia after arterial injury involves cell-specific actions mediated by TLR4
10.1161/atvbaha.115.305789 · 2015
Cathepsin L promotes vascular intimal hyperplasia after arterial injury
10.2119/molmed.2016.00222 · 2017
Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists
10.1021/jm051202e · 2006
Inflammasome modulation with P2X7 inhibitor A438079-loaded dressings for diabetic wound healing
10.3389/fimmu.2024.1340405 · 2024
Interleukin 6-regulated macrophage polarization controls atherosclerosis-associated vascular intimal hyperplasia
2022
P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation
10.3892/ijmm.2015.2129 · 2015
MTMR7 suppresses the phenotypic switching of vascular smooth muscle cell and vascular intimal hyperplasia after injury via regulating p62/mTORC1-mediated glucose metabolism
10.1016/j.atherosclerosis.2024.117470 · 2024
Smooth muscle cell Piezo1 is essential for phenotypic switch and neointimal hyperplasia
10.1111/bph.17436 · 2025
NLRP3 inflammasome activation through heart-brain interaction initiates cardiac inflammation and hypertrophy during pressure overload
10.1161/circulationaha.122.060860 · 2023
Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease
10.1161/circresaha.120.315937 · 2020
The NLRP3 inflammasome in acute myocardial infarction
10.1038/nrcardio.2017.161 · 2018
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
10.1038/s41569-023-00946-3 · 2024
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
10.1038/s41577-019-0165-0 · 2019
P2X7 receptor-mediated inflammation in cardiovascular disease
2021
Berberine regulated miR150-5p to inhibit P2X7 receptor, EMMPRIN and MMP-9 expression in oxLDL induced macrophages
2021
P2X7 receptor antagonist reduces fibrosis and inflammation in a mouse model of alpha-Sarcoglycan muscular dystrophy
10.3390/ph15010089 · 2022
Structural mechanisms of NLRP3 inflammasome assembly and activation
10.1146/annurev-immunol-081022-021207 · 2023
Smooth muscle cells in atherosclerosis: essential but overlooked translational perspectives
10.1093/eurheartj/ehaf337 · 2025
Vascular smooth muscle cells and arterial stiffening: relevance in development, aging, and disease
10.1152/physrev.00003.2017 · 2017
Vascular smooth muscle cells in atherosclerosis
10.1161/circresaha.115.306361 · 2016
How vascular smooth muscle cell phenotype switching contributes to vascular disease
10.1186/s12964-022-00993-2 · 2022
Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch
10.1172/jci.insight.142339 · 2021
TL1A inhibits atherosclerosis in apoE-deficient mice by regulating the phenotype of vascular smooth muscle cells
10.1074/jbc.ra120.015486 · 2020
In-stent restenosis: incidence, mechanisms, and treatment options
10.1007/s11886-025-02249-0 · doi-reference
Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis
10.1016/s0140-6736(15)60657-2 · doi-reference
Reversal of endothelial extracellular vesicle-induced smooth muscle phenotype transition by hypercholesterolemia stimulation: role of NLRP3 inflammasome activation
10.3389/fcell.2020.597423 · doi-reference
Protein arginine methyltransferase 5-mediated arginine methylation stabilizes Kruppel-like factor 4 to accelerate neointimal formation
10.1093/cvr/cvad080 · doi-reference
SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin
10.1007/s00018-023-04883-9 · doi-reference